Dalcetrapib - CAS 211513-37-0
Catalog number: 211513-37-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C23H35NO2S
Molecular Weight:
389.59
COA:
Inquire
Targets:
CETP
Description:
Dalcetrapib induces a conformational change in CETP, when added to human plasma. .
Purity:
>98%
Synonyms:
JTT-705; JTT705; JTT 705; RO-4607381; RO4607381; RO 4607381; Dalcetrapib.
MSDS:
Inquire
InChIKey:
YZQLWPMZQVHJED-UHFFFAOYSA-N
InChI:
InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
Canonical SMILES:
CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
1.Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation.
Yamashita S;Matsuzawa Y Curr Opin Lipidol. 2016 Oct;27(5):459-72. doi: 10.1097/MOL.0000000000000332.
PURPOSE OF REVIEW: ;To re-evaluate the functions of plasma cholesteryl ester transfer protein (CETP) in atherosclerosis based upon recent findings from human genetics and pharmacological CETP manipulation.;RECENT FINDINGS: ;CETP is involved in the transfer of cholesteryl ester from HDL to apolipoprotein B-containing lipoproteins, a key step of reverse cholesterol transport (RCT). CETP inhibitors have been developed to raise serum HDL-cholesterol (HDL-C) levels and reduce cardiovascular events. However, outcome studies of three CETP inhibitors (torcetrapib, dalcetrapib and evacetrapib) were prematurely terminated because of increased mortality or futility despite marked increases in HDL-cholesterol and decreases in LDL-cholesterol except for dalcetrapib. Patients with CETP deficiency show remarkable changes in HDL and LDL and are sometimes accompanied by atherosclerotic cardiovascular diseases. Recent prospective epidemiological studies demonstrated atheroprotective roles of CETP. CETP inhibition induces formation of small dense LDL and possibly dysfunctional HDL and downregulates hepatic scavenger receptor class B type I (SR-BI). Therefore, CETP inhibitors may interrupt LDL receptor and SR-BI-mediated cholesterol delivery back to the liver.
2.Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
Schaefer EJ;Asztalos BF Curr Opin Lipidol. 2006 Aug;17(4):394-8.
PURPOSE OF REVIEW: ;Cholesteryl ester transfer protein (CETP) inhibitors (JTT-705 and torcetrapib) are currently in clinical testing, and significantly raise high-density lipoprotein (HDL) cholesterol levels. Low HDL cholesterol is a significant independent predictor of coronary heart disease (CHD) and HDL raising has been associated with coronary heart disease risk reduction, but there is debate about whether CETP inhibition will reduce coronary heart disease risk.;RECENT FINDINGS: ;It has been documented in transgenic mouse models that apolipoprotein (apo) C-I inhibits CETP, and that high mono-unsaturated fat diets prevent the normal stimulation of CETP activity by dietary cholesterol. In rabbits, torcetrapib markedly decreases clearance of HDL cholesteryl ester via an indirect pathway, but has no effect on total plasma cholesteryl ester clearance. In humans, torcetrapib raises HDL apoA-I by modestly decreasing its fractional catabolic rate, while having a very profound effect on raising HDL cholesterol and large alpha-1 migrating HDL particles by more than 50%, with no effect on fecal cholesterol excretion. When JTT-705 at 600 mg/day was given to hypercholesterolemic patients already on pravastatin 40 mg/day, the combination was well tolerated and increases in HDL cholesterol of 28% were noted.
3.Pharmacokinetics and disposition of dalcetrapib in rats and monkeys.
Takubo H;Ishikawa T;Kuhlmann O;Nemoto H;Noguchi T;Nanayama T;Komura H;Kogayu M Xenobiotica. 2014 Dec;44(12):1117-26. doi: 10.3109/00498254.2014.932471. Epub 2014 Jun 23.
1. The pharmacokinetics and metabolism of dalcetrapib (JTT-705/RO4607381), a novel cholesteryl ester transfer protein inhibitor, were investigated in rats and monkeys. 2. In in vitro stability studies, dalcetrapib was extremely unstable in plasma, liver S9 and small intestinal mucosa, and the pharmacologically active form (dalcetrapib thiol) was detected as major component. Most of the active form in plasma was covalently bound to plasma proteins via mixed disulfide bond formation. 3. Following oral administration of (14)C-dalcetrapib to rats and monkeys, active form was detected in plasma. The active form was mainly metabolized to the glucuronide conjugate and the methyl conjugate at the thiol group. Several minor metabolites including mono- and di-oxidized forms of the glucuronide are also detected in the plasma and urine. 4. The administered radioactivity was widely distributed to all tissues and mainly excreted into the feces (85.7 and 62.7% of the dose in rats and monkeys, respectively). Most of the radioactivity was recovered by 168 h. Although the absorbed dalcetrapib was hydrolyzed to the active form and was bound to endogenous thiol via formation of disulfide bond, it was relatively rapidly eliminated from the body and was not retained.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CETP Products


CAS 1186486-62-3 Evacetrapib

Evacetrapib
(CAS: 1186486-62-3)

Evacetrapib (LY2484595) is a drug that inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low...

CP-532623
(CAS: 261947-38-0)

CP-532623, structurally related to Torcetrapib, is a potent inhibitor of cholesteryl ester transfer protein (CETP).

CAS 211513-37-0 Dalcetrapib

Dalcetrapib
(CAS: 211513-37-0)

Dalcetrapib induces a conformational change in CETP, when added to human plasma. .

CAS 939390-99-5 BMS 795311

BMS 795311
(CAS: 939390-99-5)

BMS 795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor (IC50 = 4 nM in an enzyme-based scintillation proximity assay) that inhibits choleste...

CAS 262352-17-0 Torcetrapib

Torcetrapib
(CAS: 262352-17-0)

Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low densit...

CAS 875446-37-0 Anacetrapib

Anacetrapib
(CAS: 875446-37-0)

Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LD...

Chemical Structure

CAS 211513-37-0 Dalcetrapib

Quick Inquiry

Verification code

Featured Items